Efficacy and Safety of Biologic Therapies for Treatment of Psoriasis: A Systematic Review and Observational Meta-Analysis
October 2024
in “
QJM
”
Studysummary This study compared the long-term efficacy and safety of biologics targeting TNF alpha and IL-12/23 in moderate to severe psoriasis, finding that IL-12/23 inhibitors were more effective at achieving a PASI 75 response, while both treatments showed a similar risk of serious infection and malignancy.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This systematic review and observational meta-analysis evaluates the efficacy and safety of biologic therapies, specifically anti-TNF alpha and anti IL12/23, in treating moderate to severe psoriasis. The study found that IL-12/23 inhibitors have a higher probability of achieving a PASI 75 response compared to anti-TNF alpha, with a pooled estimate of 84% versus 76.18% at year 1. Over longer periods, IL-12/23 inhibitors maintained stable efficacy, reaching 91% at year 4. Both therapies showed similar risks for serious infections and malignancy, with rates of 2.9% and 3.7% for anti-TNF alpha, and 2.4% and 3.9% for IL-12/23 inhibitors, respectively. However, anti-TNF alpha was associated with a higher rate of common adverse events compared to IL-12/23 inhibitors.
